ERBB2 and cancer: Our future research will focus on developing monoclonal neutralizing antibodies and ADCs targeting ERBB2 i14e and investigate the role of this isoform in other ERBB2 associated cancer types, ultimately enhancing the efficacy of trastuzumab-based regimens for ERBB2 i14e-expressing cancers.